Citations

Mayo Clinic

Showing 10 of 108599 citations.

Immigration, Graduate Medical Education, and Ethical Dilemmas
Bdair, Fadi, Murad, M. Hassan , Wooldridge, David , Mustafa, Reem A , Murad, M Hassan

Journal of Graduate Medical Education | June 15, 2017 | Volume: 9 | Issue: 3 | Pages: 280-282

10.4300/jgme-d-17-00124.1 | PMID 28638502 Get It

Modern reirradiation for recurrent gliomas can safely delay tumor progression
Youland, Ryan S. , Lee, John , Kreofsky, C.R., Brown, Paul D. , Uhm, Joon H. , Lee, John Y, Kreofsky, Cole R, Laack, Nadia N.

Neuro-Oncology Practice | June 15, 2017 | Volume: 5 | Issue: 1 | Pages: 46-55

10.1093/nop/npx014 | PMID 31385961 Get It

Abstract Background Despite advances in modern therapy, high-grade gliomas continue to portend a dismal prognosis and nearly all patients will experience relapse. Unfortunately, salvage options remain limited. In this study, we assessed outcomes for patients with recurrent gliomas treated with reirradiation. Methods We retrospectively identified 48 glioma patients treated with reirradiation between 2013 and 2016. All had radiographic or pathologic evidence of recurrence. Prognostic factors were abstracted from the electronic medical record. Results Initial surgery included biopsy in 15, subtotal resection in 21, and gross total resection in 12. Initial chemotherapy included temozolomide (TMZ) in 31, TMZ+dasatinib in 7, TMZ+vorinostat in 3, and procarbazine, lomustine, and vincristine in 2. The median dose of primary radiotherapy was 60 Gy delivered in 30 fractions. Median overall survival (OS) and progression-free survival (PFS) from initial diagnosis were 3.2 and 1.7 years, respectively. A total of 36 patients failed salvage bevacizumab before reirradiation. Salvage surgery was performed before reirradiation in 21 patients. Median time to reirradiation was 1.7 years. Median follow-up was 13.7 months from reirradiation. Concurrent systemic therapy was given in 33 patients (bevacizumab in 27, TMZ in 8, and lomustine in 2). Median PFS and OS after reirradiation were 3.2 and 6.3 months, respectively. Radionecrosis occurred in 4 patients and no radionecrosis was seen in patients receiving concurrent bevacizumab with reirradiation (0% vs 19%, P = .03). Conclusions Reirradiation may result in delayed tumor progression with acceptable toxicity. Prospective trials are needed to determine the impact of reirradiation on tumor progression and quality of life.
Epilepsy and mortality after aneurysmal subarachnoid hemorrhage
Harroud, Adil , Crepeau, Amy Z.

Neurology | June 15, 2017 | Volume: 89 | Issue: 3 | Pages: 222-223

10.1212/wnl.0000000000004125 | PMID 28615424 Get It

Physiology in Perspective: Structure and Function—Anatomy and Physiology Are Integral
Sieck, Gary C.

Physiology | June 15, 2017 | Volume: 32 | Issue: 4 | Pages: 264-265

10.1152/physiol.00014.2017 | PMID 28615310 Get It

Long‐term follow‐up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B–cell non‐Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) M
Witzig, Thomas E. , Johnston, Patrick B. , LaPlant, Betsy, Kurtin, Paul J. , Pederson, Levi , Moore, Dennis F., Nabbout, Nassim H., Nikcevich, Daniel A., Rowland, Kendrith M. , LaPlant, Betsy R, Pederson, Levi D , Witzig, T.E. , Grothey, Axel

American Journal of Hematology | June 14, 2017 | Volume: 92 | Issue: 10 | Pages: 1004-1010

10.1002/ajh.24824 | PMID 28614905 Get It

AbstractPatients with relapsed aggressive non‐Hodgkin lymphoma (NHL) are often treated with platinum‐based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 – 5; oxaliplatin 130 mg/m2 IV day 2; cytarabine 2000 mg/m2 IV × two doses on days 2 to 3; and pegfilgrastim 6 mg SC on day 4. Forty‐five eligible patients were accrued between 2006 and 2008. Patient characteristics were a median age of 69 years; 96% had received prior rituximab; 53% were within one year of diagnosis. The median number of cycles received was 2 (range, 1‐6). Forty‐four % received ROAD as an outpatient. The overall response rate was 71% with 27% (12/45) CR and 44% (20/45) PR. Forty‐four % (20/45) of all patients and 69% (18/26) of patients whom responded after 2 cycles proceeded to transplant. Median overall survival was 26 mos (95% CI: 7.3 mos—not reached) and median progression‐free survival was 11 mos (95% CI: 6—104 mos). There was no grade 3/4 nephrotoxicity; the rate of grade 3/4 neuropathy was 4%. Forty‐two percent of all patients and 69% of patients transplanted remain alive at 5 years. ROAD represents an acceptable salvage therapeutic option for patients with relapsed aggressive NHL.
Identification of an Alu element‐mediated deletion in the promoter region of GNE in siblings with
Garland, Jennifer, Stephen, Joshi, Class, Bradley, Gruber, Angela , Ciccone, Carla, Poliak, Aarón , Hayes, Christina, Singhal, Vandana, Slota, Christina , Perreault, John, Gavrilova, Ralitza, Shrader, Joseph A. , Joe, Galen O., Heiss, John D. , Gahl, William A. , Huizing, Marjan , Carrillo, Nuria , Malicdan, May Christine V. , Malicdan, May Christine V , Chittiboina, Prashant

Molecular Genetics & Genomic Medicine | June 14, 2017 | Volume: 5 | Issue: 4 | Pages: 410-417

10.1002/mgg3.300 | PMID 28717665 Get It

Abstract Background GNE myopathy is a rare genetic disease characterized by progressive muscle atrophy and weakness. It is caused by biallelic mutations in the GNE gene that encodes for the bifunctional enzyme, uridine diphosphate ( UDP )‐N‐acetylglucosamine (Glc NA c) 2‐epimerase/N‐acetylmannosamine (Man NA c) kinase. Typical characteristics of GNE myopathy include progressive myopathy, first involving anterior tibialis muscle and sparing the quadriceps, and rimmed vacuoles on muscle biopsy. Identifying biallelic mutations by sequencing of the GNE gene confirms the diagnosis of GNE myopathy. In a subset of patients, diagnostic confirmation is challenged by the identification of mutations in only one allele, suggesting mutations in deep intronic regions or regulatory regions. Methods We performed targeted sequencing and copy number variant ( CNV ) analysis of GNE in two siblings who clinically presented with GNE myopathy. Further molecular and biochemical studies were done to characterize the effect of a previously uncharacterized GNE mutation. Results We report two siblings of Indian descent with characteristic features of GNE myopathy, including progressive skeletal muscle weakness initially involving the anterior tibialis, and rimmed vacuoles on muscle biopsy, in which a heterozygous mutation, p.Val727Met, was identified in both affected siblings, but no other deleterious variants in either coding region or exon–intron boundaries of the gene. Subsequent insertion/deletion analysis identified a novel 11.3‐kb deletion (Chr9 [ GRC h37]: g.36257583_36268910del) encompassing the GNE promoter region, with breakpoints residing in Alu repeats. Gene expression analysis revealed reduced GNE mRNA and protein levels, confirming decreased expression of the deleted allele harboring the deletion. Conclusions We have identified GNE as one of the genes susceptible to Alu ‐mediated recombination. Our findings suggest that the deletion may encompass the promoter or another region necessary for GNE expression. In patients with typical manifestations of GNE myopathy and a single GNE variant identified, copy number variant ( CNV ) analysis may be useful in arriving at the diagnosis.
Porous Tantalum Femoral Metaphyseal Cones for Large Femoral Bone Defects in Revision Total Knee Arthroplasty
Nikolaus, O. Brant, Hanssen, Arlen D. , Lewallen, David G. , Abdel, Matthew P.

JBJS Essential Surgical Techniques | June 14, 2017 | Volume: 7 | Issue: 2 | Pages: e17

10.2106/jbjs.st.16.00096 | PMID 30233952 Get It

Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions
Kar, Siddhartha , Gayther, Simon A. , Goode, Ellen L. , Moysich, Kirsten B., Pearce, Celeste Leigh, Ramus, Susan J. , Schildkraut, Joellen M. , Sellers, Thomas A. , Berchuck, Andrew , Pharoah, Paul D.P. , Ramus, Susan J , Moysich, Kirsten , Kar, Siddhartha

Cancer Epidemiology, Biomarkers & Prevention | June 14, 2017 | Volume: 27 | Issue: 4 | Pages: 395-404

10.1158/1055-9965.epi-17-0315 | PMID 28615364 Get It

Abstract In this review, we summarize current progress in the genetic epidemiology of epithelial ovarian cancer (EOC), focusing exclusively on elucidating the role of common germline genetic variation in conferring susceptibility to EOC. We provide an overview of the more than 30 EOC risk loci identified to date by genome-wide association studies (GWAS) and describe the contribution of large-scale, cross-cancer type, custom genotyping projects, such as the OncoArray and the Collaborative Oncological Gene-Environment Study, to locus discovery and replication. We discuss the histotype-specific nature of these EOC risk loci, pleiotropy, or overlapping genetic effects between EOC and other hormone-related cancer types, and the application of findings to polygenic risk prediction for EOC. The second part of the article offers a concise review of primarily laboratory-based studies that have led to the identification of several putative EOC susceptibility genes using common variants at the known EOC risk loci as starting points. More global biological insights emerging from network- and pathway-based analyses of GWAS for EOC susceptibility are also highlighted. Finally, we delve into potential future directions, including the need to identify EOC risk loci in non-European populations and the next generation of GWAS functional studies that are likely to involve genome editing to establish the cell type–specific carcinogenic effects of EOC risk variants Cancer Epidemiol Biomarkers Prev; 27(4); 395–404. ©2018 AACR. See all articles in this CEBP Focus section, “Genome-Wide Association Studies in Cancer.”
The regulatory 1α subunit of protein kinase A modulates renal cystogenesis
Ye, Hong , Constans, Megan, Sussman, Caroline R. , Irazabal, María V. , Harris, Peter C. , Kirschner, Lawrence S. , Torres, Vicente E. , Constans, Megan M, Ye, Hong, Wang, Xiaofang , Chebib, Fouad T. , Young, William F. , Harris, Peter C , Torres, Vicente E , Irazabal, Maria V , Sussman, Caroline R.

American Journal of Physiology-Renal Physiology | June 14, 2017 | Volume: 313 | Issue: 3 | Pages: F677-F686

10.1152/ajprenal.00119.2017 | PMID 28615245 Get It

The failure of the polycystins (PCs) to function in primary cilia is thought to be responsible for autosomal dominant polycystic kidney disease (ADPKD). Primary cilia integrate multiple cellular signaling pathways, including calcium, cAMP, Wnt, and Hedgehog, which control cell proliferation and differentiation. It has been proposed that mutated PCs result in reduced intracellular calcium, which in turn upregulates cAMP, protein kinase A (PKA) signaling, and subsequently other proliferative signaling pathways. However, the role of PKA in ADPKD has not been directly ascertained in vivo, although the expression of the main regulatory subunit of PKA in cilia and other compartments (PKA-RIα, encoded by PRKAR1A) is increased in a mouse model orthologous to ADPKD. Therefore, we generated a kidney-specific knockout of Prkar1a to examine the consequences of constitutive upregulation of PKA on wild-type and Pkd1 hypomorphic ( Pkd1 RC ) backgrounds. Kidney-specific loss of Prkar1a induced renal cystic disease and markedly aggravated cystogenesis in the Pkd1 RC models. In both settings, it was accompanied by upregulation of Src, Ras, MAPK/ERK, mTOR, CREB, STAT3, Pax2 and Wnt signaling. On the other hand, Gli3 repressor activity was enhanced, possibly contributing to hydronephrosis and impaired glomerulogenesis in some animals. To assess the relevance of these observations in humans we looked for and found evidence for kidney and liver cystic phenotypes in the Carney complex, a tumoral syndrome caused by mutations in PRKAR1A. These observations expand our understanding of the pathogenesis of ADPKD and demonstrate the importance of PRKAR1A highlighting PKA as a therapeutic target in ADPKD.
Assessment and Treatment of Syncope
Shen, Win-Kuang, Sheldon, Robert S.

JAMA Cardiology | June 14, 2017 | Volume: 2 | Issue: 8 | Pages: 920

10.1001/jamacardio.2017.1784 | PMID 28614562 Get It